Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmacology,Molecular Medicine,Physiology
Reference123 articles.
1. A new therapy of Type 2 diabetes: DPP-4 inhibitors;Ábel,2011
2. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors;Gallwitz;Handb. Exp. Pharmacol.,2011
3. Insulin resistance and hyperglycaemia in cardiovascular disease development;Laakso;Nat. Rev. Endocrinol.,2014
4. Cardiovascular risk in diabetes mellitus: complication of the disease or of antihyperglycemic medications;Alvarez;Clin. Pharmacol. Ther.,2015
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antidiabetic omarigliptin dilates rabbit aorta by activating voltage‐dependent K + channels and the sarco/endoplasmic reticulum Ca 2+ ‐ATPase pump;Fundamental & Clinical Pharmacology;2022-09-26
2. Association of dipeptidyl peptidase IV polymorphism with clinicopathological characters of oral cancer;Journal of Oral Pathology & Medicine;2022-08-15
3. Analysis of Citrus Bioflavonoid Content and Dipeptidyl Peptidase-4 Inhibitory Potential of Commercially Available Supplements;Molecules;2022-07-25
4. Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study;Nutrition, Metabolism and Cardiovascular Diseases;2021-09
5. The search for dipeptidyl peptidase iv (DPP4) inhibitors for the treatment of type 2 diabetes: an in-silico study;Journal of Physics: Conference Series;2021-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3